

Resource Summary Report

Generated by [dkNET](#) on Sep 14, 2026

SK-MEL-2

RRID:CVCL_0069

Type: Cell Line

Proper Citation

RRID:CVCL_0069

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0069

Proper Citation: RRID:CVCL_0069

Description: Cell line SK-MEL-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Melanoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:2041050](#), [PMID:2784858](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6220172](#), [PMID:7718330](#), [PMID:7999427](#), [PMID:8631022](#), [PMID:8755562](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:12068308](#), [PMID:14871852](#), [PMID:15467732](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:18277095](#), [PMID:19372543](#), [PMID:19727395](#), [PMID:20164919](#), [PMID:21725359](#), [PMID:21912889](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23285177](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24576830](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25728708](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27533468](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MEL-2

Synonyms: SK-Mel-2, SK-Mel 2, SK-mel-2, SK-MEL2, SK.MEL.2, SK Mel 2, SK MEL 2, SKMEL-2, SKMEL2, SKmel2, SK-ML2, SKml2

Cross References: BTO:BTO_0003476, CLO:CLO_0009041, EFO:EFO_0002079, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:HTB-68, BioGRID_ORCS_Cell_line:1012, BioSample:SAMN03471882, BioSample:SAMN03472752, BioSample:SAMN05292464, BioSample:SAMN10988256, cancercellines:CVCL_0069, CancerTools:161915, Cell_Model_Passport:SIDM00082, CGH-DB:9322-4, ChEMBL-Cells:ChEMBL3307743, ChEMBL-Targets:ChEMBL614917, CLS:300423, Cosmic:724824, Cosmic:875885, Cosmic:897468, Cosmic:905235, Cosmic:905955, Cosmic:974073, Cosmic:974257, Cosmic:1006555, Cosmic:1022288, Cosmic:1044266, Cosmic:1045411, Cosmic:1067222, Cosmic:1092632, Cosmic:1132585, Cosmic:1155283, Cosmic:1175871, Cosmic:1303053, Cosmic:1305367, Cosmic:1458964, Cosmic:1459662, Cosmic:1477419, Cosmic:1669129, Cosmic:1995633, Cosmic:1998475, Cosmic:2159450, Cosmic:2479250, Cosmic-CLP:905955, DepMap:ACH-001190, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:905955, GEO:GSM2109, GEO:GSM50204, GEO:GSM50266, GEO:GSM188225, GEO:GSM188255, GEO:GSM188314, GEO:GSM743467, GEO:GSM750824, GEO:GSM799356, GEO:GSM799419, GEO:GSM844688, GEO:GSM844689, GEO:GSM847115, GEO:GSM887585, GEO:GSM888668, GEO:GSM1153426, GEO:GSM1181281, GEO:GSM1181359, GEO:GSM1670437, GEO:GSM1671997, GEO:GSM1672003, GEO:GSM1672044, GEO:GSM1672075, GEO:GSM1672083, GEO:GSM1672088, GEO:GSM1672104, GEO:GSM1672117, GEO:GSM1672126, GEO:GSM2124650, IARC_TP53:18086, KCLB:30068, LINCS_LDP:LCL-1256, NCI-DTP:SK-MEL-2, PharmacoDB:SKMEL2_1394_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030206, PRIDE:PXD030304, Progenetix:CVCL_0069, PubChem_Cell_line:CVCL_0069, SKY/M-FISH/CGH:2820, Wikidata:Q54953905

ID: CVCL_0069

Record Creation Time: 20220427T221545+0000

Record Last Update: 20260913T010043+0000

Ratings and Alerts

No rating or validation information has been found for SK-MEL-2.

No alerts have been found for SK-MEL-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 362 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. *Cancer research*, 86(5), 1194.

Watterson A, et al. (2026) CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance. *Cell reports. Medicine*, 7(1), 102565.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. *Molecular cell*, 86(8), 1546.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. *Cancer research*, 85(9), 1611.

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF β complex for genomic stability. *Cell reports*, 44(11), 116495.

Cerqua M, et al. (2025) The integrated stress response drives MET oncogene overexpression in cancers. *The EMBO journal*, 44(4), 1107.

Imumkachi N, et al. (2025) Tryptophan-Conjugated Carbon Dots with Enhanced Cellular Uptake as a Potential Drug Delivery System for Melanoma. *ACS applied bio materials*, 8(12), 11047.

Fu X, et al. (2025) A cancer-specific antigen drives histone acetylation by stabilizing the acetyltransferases. *Cell reports*, 44(10), 116408.

Kim DY, et al. (2025) Identification of UBE3C as an E3 ubiquitin ligase for mutant BRAF. *Life sciences*, 378, 123827.

Parihar K, et al. (2025) Tissue-dependent mechanosensing by cells derived from human tumors. *npj biological physics and mechanics*, 2(1), 19.

Panda PK, et al. (2025) BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1333.

Foote JB, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. *Cancer research*, 85(5), 956.

Mizuno Y, et al. (2025) Focal Adhesion Kinase-Dependent Reprogramming of IFN- γ Signaling through PYK2 Coinhibition Sensitizes Melanoma to Immune Checkpoint Blockade. *The Journal of investigative dermatology*.

Weinstein HNW, et al. (2024) RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4. *Cell reports*, 43(8), 114622.

Mukherjee S, et al. (2024) "Radical" differences between two FLIM microscopes affect interpretation of cell signaling dynamics. *iScience*, 27(7), 110268.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Tubita A, et al. (2024) Latent-Transforming Growth Factor β -Binding Protein 1/Transforming Growth Factor β 1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma. *The American journal of pathology*, 194(8), 1581.

Cai C, et al. (2024) NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth. *Molecular cancer research : MCR*, 22(4), 386.

Yue C, et al. (2024) The role of PKP1 in tumor progression in melanoma: Analysis of a cell adhesion-related model. *Environmental toxicology*, 39(2), 915.